Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novo Nordisk is venturing into the molecular glue degrader space with a multi-target deal with San Diego-based Neomorph worth up to $1.46 billion in biobucks.…
Neomorph has landed a multi-target collaboration with Novo Nordisk worth up to $1.46 billion in potential payments across multiple programs, plus upfront,…
Apr 17, 2026: Neomorph closed a $100M Series B led by Deerfield Management (with Regeneron Ventures, Longwood, Alexandria, Binney Street). Funds the Phase…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Neomorph entered multi-target collaboration and licensing agreement with Novo Nordisk for molecular glue degraders in cardiometabolic and rare diseases. Total deal value up to $1.46B across multiple targets, plus upfront, R&D funding, and tiered royalties. Neomorph leads discovery and preclinical work with Novo Nordisk holding exclusive clinical and commercialization rights.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Neomorph Inc. (this deal) | 2024 | $1.5B | — |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
← Browse all deals · How we score deals
More: 2024 deals · Novo Nordisk A/S deals · Rare Disease deals